Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | CASP7 | P55210 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.46 |
| ▸ | HBB | P68871 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872035 | 0.96 | SLC16A3 (0.60) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13238299 | 0.90 | SLC16A3 (0.64) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13238301 | 0.90 | SLC16A3 (0.55) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL23872036 | 0.86 | SLC16A3 (0.67) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13238305 | 0.84 | SLC16A3 (0.52) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL18517777 | 0.84 | SLC16A3 (0.66) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13238317 | 0.84 | SLC16A3 (0.69) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL13238303 | 0.84 | SLC16A3 (0.58) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL18712645 | 0.83 | SLC16A3 (0.57) | SLC16A3ALDH1A1USP2MEN1KMT2A | |
| SCHEMBL2956918 | 0.83 | SLC16A3 (0.67) | SLC16A3ALDH1A1USP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1842923-B1 | Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them | ROCHE DIAGNOSTICS GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| US-7759470-B2 | Labeling reagent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759470-B2 | Labeling reagent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1842923-A1 | Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them. | Roche Diagnostics GmbH (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196852-A1 | Labeling reagent | INMT, RNGTT, DUT | SLC16A3 1443/4885ALDH1A1 458/4885USP2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.